Zydus Lifesciences gets EIR report for API Ahmedabad facility

11 Mar 2024 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the USFDA for the inspection conducted at the API Ahmedabad facility. The company had earlier received Post Application Action Letter from the USFDA for the same inspection confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent an inspection from December 14 to 22, 2023 and has been classified as Voluntary Action Indicated (VAI).

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

899.25 4.25 (0.47%)
13-Jan-2026 15:40 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1728.95
Dr. Reddys Lab 1190.35
Cipla 1448.15
Zydus Lifesciences 899.25
Lupin 2170.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×